Fukuda, Yosuke
Nakao, Shintaro http://orcid.org/0000-0003-4200-0052
Kaizu, Yoshihiro
Arima, Mitsuru
Shimokawa, Sakurako
Wada, Iori
Yamaguchi, Muneo
Takeda, Atsunobu
Sonoda, Koh-Hei
Funding for this research was provided by:
Japan Society for the Promotion of Science (20K09829)
Alcon Pharma Research
the Foundation for the Advancement of Clinical Medicine
Article History
Received: 17 March 2022
Revised: 12 May 2022
Accepted: 27 May 2022
First Online: 4 June 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the (place name of institution and/or national research committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from all patients after a detailed explanation of the study.
: Shintaro Nakao has received consulting fee from Kowa and travel reimbursements and speaker fees from Novartis, Bayer Pharma, Canon Inc., Santen Pharmaceutical, Kowa, Senju Pharmaceutical, Ono Pharmaceutical, and MSD in the subject matter or materials discussed in this manuscript. The other authors have no financial disclosures: Yosuke Fukuda, Yoshihiro Kaizu, Mitsuru Arima, Sakurako Shimokawa, Iori Wada, Muneo Yamaguchi, and Atsunobu Takeda. All authors attest that they met the current ICMJE criteria for authorship.